Our investment banking clients often ask us to help identify emerging competitors – high-growth firms still small enough to sit outside the top of the league tables. A year ago, Cantor Fitzgerald fit the bill, as an established trading and ATM player beginning to move into underwritten ECM deals. Today, Cantor’s growing ECM clout is well-known to any bank active in the Healthcare sector. Cantor finished 2017 as the #9 Life Sciences ECM bank, earning more underwriting fees than banks like Barclays and Credit Suisse. Cantor has also been a key beneficiary of the continuing SPAC IPO surge.
Given Cantor’s top-10 position in its U.S. focus markets – Life Sciences and SPACs – can it continue its exponential growth trajectory into 2018? Bloomberg reports that Cantor recently hired a group of more than 20 Jefferies bankers to cover the Power & Renewables space. Cantor also brought on RBC and Goldman Sachs group heads to run Convertible Bond origination and sales. With Healthcare IB activity booming, and expansion plans underway, Cantor should remain a growing ECM force in 2018.